Onco Actu du 5 juillet 2016

	1. Biologie
Building tumours in the lab – a how to guide [Cancer Research UK] With their plan in hand, the team is starting to put the pieces of an artificial tumour in place. And for now, they are focusing on ovarian cancer.
The visualizations transforming biology [Nature News & Comment] Inventive graphic design and abstract models are helping researchers to make sense of a glut of data.
	3.2 Prévention - Obésité
To help prevent childhood obesity we need action on TV junk food advertising [Cancer Research UK] Ofcom, the UK’s communications regulatory body, has previously acknowledged the harm that these ads cause to children and introduced a ban on ads promoting junk food during children’s programming. But it isn’t enough. That’s the conclusion of new report published today by Cancer Research UK’s Policy Research Centre for Cancer Prevention and NatCen, Britain’s leading independent social research institute.
	4.2 Dép., diag. & prono. - Génome
Laying the foundations for genomic medicine in France [PHG Foundation] One commentary claims that only the French project is firmly focused on healthcare integration whereas international counterparts such as the US Precision Medicine Initiative and the 100KGP are primarily research projects; hopefully the English example will rapidly prove this view incorrect.
	4.7 Dép., diag. & prono. - Col de l'utérus
HPV cervical cancer test introduced in England [BBC News] Until now, an HPV test has only been done if doctors noticed abnormal cells in the smear sample.
	5.2 Pharma
Positive results for Yeliva in advanced solid tumour study [European Pharmaceutical Review] By inhibiting the SK2 enzyme, Yeliva blocks the synthesis of sphingosine 1-phosphate (S1P), a lipid signalling molecule that promotes cancer growth and pathological inflammation.
	5.3 Traitements - FDA, EMA,...
Independence would be good for the FDA and the public [STAT] To be sure, there will always be bureaucratic hurdles. That’s the nature of government. But any effort that can recalibrate the balance between bureaucracy and resources should be pursued. The FDA deserves a seat at the table where decisions are made.
	5.4 Traitements - Economie
These 20 Recently Approved Cancer Drugs Essentially Have 1 Thing in Common [The Motley Fool] With the exception of Yondelis, a chemotherapy treatment administered to treat soft tissue sarcomas, there isn't a single cancer drug approved since September 2014 that costs less than $104,000 annually at the wholesale level.
	6. Lutte contre les cancers
NICE guidance on end of life care for children aims to end inconsistences in treatment [NICE] An estimated 40,000 children and young people are terminally ill in England. The quality of care they receive varies across the country. Draft guidance from NICE (National Institute for Health and Care Excellence) outlines what the best palliative care for children looks like.
	6.10 Politiques
Why Brexit is bad news for cancer research [The Guardian] Ultimately for a newly-disadvantaged British research scientist like myself, the lure of working and settling overseas has never been greater.
	6.11 Patients
Breast cancer survivors not always clear about follow up care [Reuters] “This study confirms patients’ misconceptions of what the purpose and goals of follow up care is all about.” Lyman, who was not involved with the study, recommends that doctors be clear with their patients as to why certain tests are necessary and others aren’t.
	6.7.2 Applis
New smartphone app shows how cancer treatments work [Cancer Research UK] The new app allows the public to test out three different cancer therapies on a virtual tumour to see how these treatments stimulate the immune system to destroy cancer cells.